312 results
Page 4 of 16
8-K
EX-99.1
neat9 kso3
21 Apr 21
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
8:45am
8-K
EX-10.1
oo6x23fqf ayl
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm
8-K
EX-10.1
dxtguk s90r
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-99.1
n7y0az
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-99.2
rhgg0
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
424B5
nwhvbvaryz6t3 yzbsk
12 Feb 21
Prospectus supplement for primary offering
12:00am
S-3ASR
EX-4.6
co9b88tk
10 Feb 21
Automatic shelf registration
6:04am
S-3ASR
wvir zioh4vhumplh63r
10 Feb 21
Automatic shelf registration
6:04am
S-3ASR
EX-4.5
4kqtibh3
10 Feb 21
Automatic shelf registration
6:04am
8-K
EX-99.1
tf1w8 efx23sm
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.2
mtp zzwranq
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
tgisyaij
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-10.1
nzvr srzo5uq
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-99.1
1janpqh4 4xx
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
424B5
o3nl7aysy4lnjj1f4p
16 Nov 20
Prospectus supplement for primary offering
12:21pm
8-K
EX-1.1
4k5avp jn
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
8-K
EX-99.1
egjues8xgazk rx5w4au
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
8-K
EX-99.2
88rp5
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm